Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|June 16, 2026 (Updated: June 10, 2026)

The BioPharm Brief: Dual Targets, Treg Therapy, Tumor Responses

Early clinical data highlight advances in bispecific antibodies and immune modulation, with new findings in Type 2 inflammatory diseases, alopecia areata, and platinum-resistant ovarian cancer.

https://embeds.audioboom.com/posts/8917469/embed?v=202301

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today's update focuses on three early-stage clinical programs that are exploring different ways to harness the immune system against inflammatory diseases and cancer.

First, Bambusa Therapeutics reported positive preliminary phase 1 multiple ascending dose data for BBT002, a bispecific antibody designed to target both IL-4 receptor alpha and IL-5. The investigational therapy demonstrated sustained suppression of multiple biomarkers associated with Type 2 inflammation, including eosinophils, TARC, and pSTAT6. Researchers also reported a half-life of approximately 29 days, supporting the potential for extended dosing intervals as the program advances into studies in chronic obstructive pulmonary disease and chronic rhinosinusitis with nasal polyps.

Next, HCW Biologics announced preliminary phase 1 findings for HCW9302, an IL-2 biased fusion immunotherapeutic being evaluated in patients with alopecia areata. The therapy is designed to expand regulatory T cells, which help maintain immune tolerance. Early results showed reductions in disease severity among treated patients while maintaining a favorable safety profile, providing an initial signal that immune modulation through regulatory T-cell expansion may represent a novel approach for autoimmune hair loss.

Finally, Context Therapeutics reported encouraging interim phase 1 results for CTIM-76, a Claudin 6 directed T-cell engager being studied in platinum-resistant ovarian cancer. The company reported a 29% confirmed overall response rate among evaluable patients, a notable finding in a population that had received multiple prior lines of therapy. Investigators also reported a manageable safety profile, supporting continued development of the program.

While these programs target very different diseases, all three underscore a broader trend in drug development. Companies are increasingly designing therapies that fine tune immune activity with greater precision, whether by blocking multiple inflammatory pathways, restoring immune balance, or directing immune cells toward cancer targets.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Insights

  • MBX's canvuparatide delivered sustained one-year results in chronic hypoparathyroidism and remains on track for phase 3.
  • Gan & Lee reported positive metabolic disease data across diabetes, obesity, and liver disease programs.
  • Novartis advanced its FSHD program with positive biomarker results supporting ongoing Phase 3 development.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more